NCT03150316Unknown1 期
A Phase I, Open-Label, Multi-Center Study of CKD-581 in Combination With Lenalidomide and Dexamethasone in Patients With Previously Treated Multiple Myeloma
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 入组人数
- 18
- 试验地点
- 2
- 主要终点
- MTD
研究概览
简要总结
This study is to determine the maximum tolerated dose(MTD) and recommened phase 2 dose(RP2D) based on dose limiting toxicity(DLT), and to evaluate safety and pharmacokinetics(PK) profile of a single agent CKD-581 injection in Combination with Lenalidomide and Dexamethasone in patients with Previously Treated Multiple Myeloma.
详细描述
This is an open label, dose escalation study. Cohort of 3~6 patients receive escalation doses of CKD-516 until the maximum tolerated dose(MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose limiting toxicity.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •must have received at least two prior lines of therapy and Diagnosis of symptomatic multiple myeloma(IMWG 2015)
- •Eastern Cooperative Oncology Group performance status ≤ 2
- •Life expectancy 12 weeks
- •must have the following laboratory values within 3 weeks prior to first dose of study drug
- •absolute neutrophil count(ANC) ≥ 1,500 mm3
- •platelet count(PLT)≥ 100,000 mm3
- •Hb ≥ 9.0g/dL
- •AST(SGOT) and ALT(SGPT) ≤ 3 x upper limit of normal(UNL)
- •Serum bilirubin ≤ 1.5 x ULN (but, Gilbert syndrome ≤ 3 x UNL)
- •Creatinin Clearance(CrCl) ≤ 50mL/min
- •One more measureable disease following values
- •Serum M-protein ≥ 1g/dL
- •Urine M-Protein ≥ 200mg/24hr
- •in that case serum M-protein, urine M-Protein nonmeasurable and FLC ratio abnormal, Serum free light chain(FLC) level ≥ 100mg/L(≥10mg/dL)
- •more than 24 weeks prior to last lenalidomide dose
- •must have signed the consent form
排除标准
- •Patients with CNS disease
- •Patients with clinically significant heart disease within 24weeks prior to first dose of study drug
- •patients with clinically significans abnormal EKG, echocardiography at screening
- •patients with patients with embolism within 24 weeks
- •patients with active hepatitis, HIV positive(exception, non active hepatitis)
- •peripheral neuropathy ≥ CTCAE grade 2 within 2 weeks prior to first dose of study drug
- •Patients with clinically significant disease
- •Patients with a prior malignancy with in the last 3 years except adequately treated basal cell or squamous cell or skin cancer, in situ cervical cancer
- •Patients who have received surgery, chemotherapy, radiation therapy or immunotherapy or any other investigational drugs ≤ 4 weeks prior to first dose of study drug and during treatment period
- •Patients who can not anticoagulate
- •Patients who have received dexamethasone >10mg/day within 2week prior to first dose of study drug and during treatment period
- •Women who are pregnant or breast feeding or women of childbearing potential not using an effective method of birth control. Male patients whose sexual partners are not using effective birth control.
- •patients with hypersensitive reaction of lenalidomide or dexamethasone
研究组 & 干预措施
Treat Regimen
Experimental
CKD-581(investigational Drug) Lenalidomide Dexamethasone
干预措施: Treat Regimen (Drug)
结局指标
主要结局
MTD
时间窗: Up to 28 days(for 1st cycle)
Maximum Tolerated Dose
次要结局
- Pharmacokinetics(Cmax)(1st Cycle day1: up to 24hr)
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
1 期
CKD-581 + Bortezomib + Dexamethasone in Patients With Previously Treated Multiple MyelomaMyeloma, MultipleNCT03051841Chong Kun Dang Pharmaceutical18
终止
1 期
E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125Ovarian CancerNCT01133756Eisai Inc.7
已完成
1 期
Phase 1 Study Of Aurora Kinase Inhibitor PF-03814735 In Patients With Advanced Solid TumorsSolid TumorsNCT00424632Pfizer57
已完成
1 期
Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic LeukemiaIndolent Non-Hodgkin LymphomaChronic Lymphocytic LeukemiaMantle Cell LymphomaNCT01410513Sanofi37
终止
1 期
A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET AmplificationNon-Small Cell Lung CancerNCT02468661Novartis Pharmaceuticals23